Artivion (AORT)
(Delayed Data from NYSE)
$26.85 USD
+1.09 (4.23%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $26.86 +0.01 (0.04%) 6:46 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.85 USD
+1.09 (4.23%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $26.86 +0.01 (0.04%) 6:46 PM ET
3-Hold of 5 3
C Value A Growth D Momentum B VGM
Zacks News
Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 133.33% and 0.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ClearPoint Neuro (CLPT) delivered earnings and revenue surprises of 15.79% and 4.84%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inogen (INGN) delivered earnings and revenue surprises of 55.56% and 7.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Alphatec (ATEC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Alphatec (ATEC) delivered earnings and revenue surprises of -11.54% and 0.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in AxoGen (AXGN): Can Its 5.4% Jump Turn into More Strength?
by Zacks Equity Research
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Artivion (AORT) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 200% and 5.56%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
Artivion, Inc. (AORT) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Medical Stocks Lagging Artivion (AORT) This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Cencora (COR) have performed compared to their sector so far this year.
3 Buy-Rated Small Caps Flexing Big Growth
by Derek Lewis
Small-cap stocks can be solid considerations for those who can handle a higher level of volatility. Analysts have recently become bullish on these three.
Buy 5 Medical Devices Stocks for a Stable Portfolio in 2024
by Nalak Das
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These are: AORT, TMDX, DXCM, SWAV, EW.
Is Artivion (AORT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Astria Therapeutics, Inc. (ATXS) have performed compared to their sector so far this year.
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Artivion, Inc. (AORT) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Artivion (AORT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Think Artivion (AORT) Could Surge 30.7%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 30.7% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Artivion (AORT) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 184.62% and 4.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Artivion (AORT) have performed compared to their sector so far this year.
Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Intuitive Surgical, Inc. (ISRG) and Artivion (AORT) have performed compared to their sector so far this year.
Has AN2 Therapeutics (ANTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how AN2 Therapeutics, Inc. (ANTX) and Artivion (AORT) have performed compared to their sector so far this year.
Wall Street Analysts Believe Artivion (AORT) Could Rally 44.41%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 44.4% in Artivion (AORT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Artivion (AORT) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Artivion (AORT) and Augmedix, Inc. (AUGX) have performed compared to their sector so far this year.
Molina Healthcare (MOH) Wins Medicaid Deal From New Mexico HSD
by Zacks Equity Research
Molina Healthcare (MOH) receives a contract from the New Mexico HSD, subsequent to which it can effectively serve the statewide Medicaid members.
Time to Buy These Medical Stocks as Earnings Approach
by Shaun Pruitt
Quarterly results from large retailers will highlight this week's earnings lineup but there are a few healthcare companies that investors will want to pay attention to as well.